As news about some countries pausing its deployment spread, the pressure rises on other countries to follow suit, as they weigh the risk of public mistrust.
If in the near future, public mistrust about this brand of vaccine climbs higher but confidence in other vaccines does not drop as much, then governments will benefit from having deferred deployment of this vaccine, and they may benefit further by suspending deployment of this vaccine entirely, even if the vaccine is entirely vindicated to be safe.
This outcome would be unfair for the manufacturer, but it would sacrifice this brand to preserve public trust. Public trust is a key factor in healthcare policy in societies where some healthcare participation is voluntary and elections can significantly influence policy priorities.